Many trials fail to produce results and to translate into

Postdiagnosis/pretreatment exercise may lower risk of recurrence of breast cancer,

With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to

A retrospective analysis of patients treated with locoregional therapy but

A PET-based, pathological complete response-adapted strategy leads to excellent 3-year

In the phase II aceIERA trial, giredestrant was well tolerated

Addition of palbociclib to fulvestrant did not improve progression-free survival,

With the passing of Pinuccia Valagussa, co-founder of the Michelangelo

A new review from Italian researchers summarizes evidence of efficacy

The final analysis of phase III PEONY trial confirms a

Results from the NATALEE trial show disease-free survival benefits with

INAVO120 trial primary analysis shows benefits with inavosilib added to

Higher pathologic complete response rate with atezolizumab added to anthracycline

A phase I/II trial shows that this HER3-targeted antibody-drug conjugate

An individual patient data metanalysis suggests that oral SERDs improve

A study from Michelangelo Foundation researchers in collaboration with San

No Event-free survival improvement by addition of atezolizumab to neoadjuvant

The phase 3 trial TROPiCS-02 shows that the antibody-drug conjugate

The SUMMIT study shows that the combination of neratinib, fulvestrant

A canadian study shows that screening programs for women in

A new study by the Michelangelo Foundation, in collaboration with

The phase 2 DAISY trial suggests that HER2 expression is

Oncotype DX helps to decrease discordancy in adjuvant chemotherapy recommendations

Among selected patients with previous hormone receptor–positive early breast cancer,

PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast

Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable

Anthracycline plus taxane regimens are among the most efficacious at

The GELATO trial shows the feasibility of trials specifically designed

Patients with HER2-positive early breast cancer who achieve a pathologic

ctDNA and residual cancer burden after neoadjuvant systemic therapy are

The effects of omission of radiotherapy after surgery on local

Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA

Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in

This multicentric machine learning model improves performance of local models

Foundation’s experts and data in key educational sessions to share

Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a

NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as

Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did

CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and